Diabetes Care, Vol 20, Issue 10 1594-1597, Copyright © 1997 by American Diabetes Association

ARTICLES

Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group

P Oskarsson, JG Ljunggren and PE Lins
Department of Internal Medicine, Danderyd Hospital, Sweden.

OBJECTIVE: To investigate the efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. RESEARCH DESIGN AND METHODS: A total of 216 insulin-treated diabetes patients with painful diabetic neuropathy were randomly allocated to three dosages of mexiletine or placebo. The Visual Analog Scale (VAS) for pain/discomfort was scored each day during daytime and nighttime, and sleeping disturbances were also recorded by the patients. Plasma levels of mexiletine and 24-h electrocardiogram (ECG) mapping were assessed before and during the 3-week study period. RESULTS: A significant reduction in sleep disturbances and pain during nighttime was observed in the group of patients taking the highest dosages (675 mg/day) of mexiletine compared with the other groups. No significant correlation was found between plasma concentration of mexiletine and the therapeutic effect or adverse events. No serious adverse events were seen. The 24-h ECG mapping did not disclose onset of significant arrhythmias in any patient. CONCLUSIONS: Mexiletine in a dosage of 675 mg daily can reduce pain caused by diabetic neuropathy, and the effect of this drug appears to have a rapid onset.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. M. Huizinga and A. Peltier Painful Diabetic Neuropathy: A Management-Centered Review Clin. Diabetes, January 1, 2007; 25(1): 6 - 15. [Abstract] [Full Text] [PDF]

				T. S. Foster Efficacy and Safety of {alpha}-Lipoic Acid Supplementation in the Treatment of Symptomatic Diabetic Neuropathy The Diabetes Educator, January 1, 2007; 33(1): 111 - 117. [Abstract] [Full Text] [PDF]

				I. W. Tremont-Lukats, V. Challapalli, E. D. McNicol, J. Lau, and D. B. Carr Systemic Administration of Local Anesthetics to Relieve Neuropathic Pain: A Systematic Review and Meta-Analysis Anesth. Analg., December 1, 2005; 101(6): 1738 - 1749. [Abstract] [Full Text] [PDF]

				C. F. Corbett Practical Management of Patients With Painful Diabetic Neuropathy The Diabetes Educator, July 1, 2005; 31(4): 523 - 540. [Abstract] [Full Text] [PDF]

				A. Nathan, J. B. Rose, J. W. Guite, D. Hehir, and K. Milovcich Primary Erythromelalgia in a Child Responding to Intravenous Lidocaine and Oral Mexiletine Treatment Pediatrics, April 1, 2005; 115(4): e504 - e507. [Abstract] [Full Text] [PDF]

				J. R. Mendell and Z. Sahenk Painful Sensory Neuropathy N. Engl. J. Med., March 27, 2003; 348(13): 1243 - 1255. [Full Text] [PDF]

				J. S. Gimbel, P. Richards, and R. K. Portenoy Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial Neurology, March 25, 2003; 60(6): 927 - 934. [Abstract] [Full Text] [PDF]

				M. Backonja, A. Beydoun, K. R. Edwards, S. L. Schwartz, V. Fonseca, M. Hes, L. LaMoreaux, E. Garofalo, and for the Gabapentin Diabetic Neuropathy Study Group Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: A Randomized Controlled Trial JAMA, December 2, 1998; 280(21): 1831 - 1836. [Abstract] [Full Text] [PDF]